Corporate Finance Adviser to

Corporate Finance Adviser to
on its initial fundraising of $8m

Corporate Finance Adviser to Fastnet Oil & Gas plc

Corporate Finance Adviser to  Fastnet Oil & Gas plc
on the farm-out to SK Innovation of a 12.5% interest in the Foum Assaka licence, offshore Morocco

Corporate Finance Adviser to

Corporate Finance Adviser to
on its £10m Equity Placing in November 2013

Corporate Finance Adviser to

Corporate Finance Adviser to
on its £10m IPO on the AIM market of the London Stock Exchange

Trade Sale Advisor to Major Shareholder of

Trade Sale Advisor to Major Shareholder of
on its sale to RSA for €65m

Trade Sale Adviser to

Trade Sale Adviser to
  on its sale to Affinion International for €20m+

Trade Sale Adviser to

Trade Sale Adviser to
on its sale to Exponent Private Equity for €170m

Trade Sale Adviser to

Trade Sale Adviser to
on its sale to NASDAQ quoted Verint Systems for $20m+

Trade Sale Adviser to EMAP Plc

Trade Sale Adviser to EMAP Plc
on the Sale of its Irish Radio Assets for €200m

natural-resources-banner

Raglan Pharmaceutical & Life Science Projects

Raglan Capital is involved in a number of pharmaceutical and life science ventures including Amryt Pharma plc, and Open Orphan.

Amryt Pharmaceuticals plc

fasnet-logo-reflectAmryt Pharma is a specialty pharmaceutical company focused on the developing and delivering innovative new treatments to help improve the lives of patients with rare and orphan diseases.

Amryt’s earlier stage products are focussed on developing novel, next generation somatostatin analogue (“SSA”) peptide medicines for patients with rare neuroendocrine diseases, where there is high unmet medical needs. These include acromegaly and Cushing’s disease.

Amryt Pharma is listed on AIM and ESM. Further details can be found on www.amrytpharma.com

Open Orphan

open-orphan-logo-reflectOpen Orphan is a recently established orphan drug company focused on bringing new orphan drugs to rare disease patients with high unmet medical needs in the EMEA (Europe, Middle East and Africa) region. The company is led by an experienced Board and management team with expertise in orphan drug regulatory approval, market access and reimbursement, commercialisation and launch optimisation.

Open Orphan is a business concept and a company created in-house by Raglan that follows on the success and learnings of our first life science project, Amryt Pharma plc. However, this time Open Orphan aims to quickly build up a portfolio of in-licensed Orphan Drugs (drugs for rare conditions) in the EU while avoiding the risk of large, expensive clinical trials. By doing this, Open Orphan can avoid R&D expenditure while also benefiting from near-term revenue potential. Many mid-sized and smaller North American pharma companies have tended to overlook or avoid the EU market for Orphan Drugs as they see it as far more complex and difficult to navigate than the North American landscape.

Open Orphan has built the in-house capability to in-license, get EMA approval and pan-EU reimbursement for, launch and commercialise Orphan Drugs in its selected regions. Moreover, the company plans to acquire a European based drug reimbursement, sales & marketing consultancy firm which will not only complement its capabilities but also drive ongoing consulting revenue going forward.

Open Orphan can be found on www.openorphan.com